User:Mr. Ibrahem/Estradiol cypionate/medroxyprogesterone acetate

From Wikipedia, the free encyclopedia
Estradiol cypionate /
medroxyprogesterone acetate
Estradiol cypionate (top) and medroxy-
progesterone acetate (bottom)
Combination of
Estradiol cypionateEstrogen
Medroxyprogesterone acetateProgestogen
Clinical data
Trade namesCyclofem, Lunelle, others[1]
Other namesEC/MPA; Cyclo-Provera; HRP-112
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Intramuscular injection
Legal status
Legal status

Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control.[3] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin.[3] It is recommended for short-term use and is given once a month by injection into a muscle.[4]

Common side effects of EC/MPA include irregular menstrual periods which typically improves with time.[4] Other side effects include blood clots, headache, hair loss, depression, nausea, and breast pain.[4][5] Use during pregnancy is not recommended.[3] Use during breastfeeding is likely safe.[6] It works mainly by preventing ovulation.[3]

EC/MPA came into medical use in 1993 with approval in the United States in 2000.[7][3] It is on the World Health Organization's List of Essential Medicines.[8] The medication is approved for use in 18 countries.[9] It is used in Mexico, Thailand, and Indonesia, among other countries.[7] It is no longer commercially available in the United States.[3]

References[edit]

  1. ^ Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to; Organization, World Health; Cancer, International Agency for Research on (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. p. 431. ISBN 9789283212911. Archived from the original on 2017-01-02.
  2. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 15 September 2020.
  3. ^ a b c d e f "Estradiol and medroxyprogesterone Intramuscular Advanced Patient Information - Drugs.com". www.drugs.com. Archived from the original on 1 January 2017. Retrieved 1 January 2017.
  4. ^ a b c World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 368–370. hdl:10665/44053. ISBN 9789241547659.
  5. ^ "Estradiol/medroxyprogesterone Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 1 January 2017. Retrieved 1 January 2017.
  6. ^ "Estradiol / medroxyprogesterone (Lunelle) Use During Pregnancy". www.drugs.com. Archived from the original on 1 January 2017. Retrieved 1 January 2017.
  7. ^ a b Senanayake, Pramilla; Potts, Malcolm (2008). Atlas of Contraception, Second Edition (2 ed.). CRC Press. p. 51. ISBN 9780203347324. Archived from the original on 2017-01-02.
  8. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. ^ Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357. Archived from the original (PDF) on 2017-08-10. Retrieved 2018-08-02.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Estradiol_cypionate/medroxyprogesterone_acetate&oldid=1062243700"